clinical trial · NCT06403436
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Advanced Solid TumorAdult Solid TumorAdult DiseaseCancerNSCLCEGFRKRAS G12CSquamous Cell Lung CancerTT125-802
brief summary
The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.
started
Nov 7, 2023
primary completion
Aug 1, 2026
completion
Dec 1, 2026
last updated
Apr 13, 2026
detailed description
The purpose of this Phase 1, First-in-Human, Open-label Study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of TT125-802 as single agent in subjects with advanced solid tumors.
official title
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol